Fc gamma RIIIA/CD16a Antibody (DJ130c) [DyLight 488]
Novus Biologicals, part of Bio-Techne | Catalog # NB100-64346G
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin
Label
DyLight 488 (Excitation = 493 nm, Emission = 518 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # DJ130c
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for Fc gamma RIIIA/CD16a Antibody (DJ130c) [DyLight 488]
Immunogen
CD34 antigen
Reactivity Notes
Reacts with: Macaque
Specificity
NB100-64346 recognizes human CD16, a 50-65kD cell surface molecule, which is the low affinity receptor for IgG (FcR III). CD16 exists as a transmembranous form (Fc gammaRIIIA, or CD16A) and a glycosyl phosphatidylinositol (GPI) anchored form (Fc gammaRIIIB, or CD16B). CD16A is expressed by NK cells, some T cells, and macrophages, whereas CD16B is primarily expressed by granulocytes. In addition, CD16B exists as two allelic variants NA1 and NA2. DJ130c recognizes all polymorphonuclear cells irrespective on their NA phenotype. Studies show that the DJ130c antibody recognizes an epitope in the first membrane-distal domain of CD16 and recognizes both CD16A and CD16B.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Description
This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Applications for Fc gamma RIIIA/CD16a Antibody (DJ130c) [DyLight 488]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Frozen
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Fc gamma RIIIA/CD16a
Activating NK cell receptor function has been harnessed for its potential in tumor immunotherapy (5). One immunotherapy strategy is using bi- and tri-specific NK cell engagers (BiKE and TriKE) to target the Fc gamma RIIIA/CD16a receptor with tumor-associated antigens to stimulate a cytotoxic response and mount an attack on tumor cells (5). CD16a is also capable of antibody dependent cellular cytotoxicity (ADCC) through recognition of antibodies bound to target cells (5-6). CD16-induced NK cell activation allows for NK co-receptor expression including stimulatory receptors like CD137 or inhibitory receptors like TIGIT and PD-1, which serve as additional regulatory checkpoints during ADCC (6). Therapeutic antibodies for cancer treatment like rituximab or trastuzumab can be recognized by Fc gamma RIIIA/CD16a to activate NK cell-mediated killing of tumor cells (5-6).
References
1. Fossati, G., Bucknall, R. C., & Edwards, S. W. (2001). Fcgamma receptors in autoimmune diseases. European Journal of Clinical Investigation, 31(9), 821-831. https://doi.org/10.1046/j.1365-2362.2001.00881.x
2. Patel, K. R., Roberts, J. T., & Barb, A. W. (2019). Multiple Variables at the Leukocyte Cell Surface Impact Fc gamma Receptor-Dependent Mechanisms. Frontiers in Immunology, 10, 223. https://doi.org/10.3389/fimmu.2019.00223
3. Moldovan, I., Galon, J., Maridonneau-Parini, I., Roman Roman, S., Mathiot, C., Fridman, W. H., & Sautes-Fridman, C. (1999). Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. Immunology Letters, 68(1), 125-134. https://doi.org/10.1016/s0165-2478(99)00041-3
4. Uniprot (P08637)
5. Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., & Moretta, L. (2021). NK cells and ILCs in tumor immunotherapy. Molecular Aspects of Medicine, 80, 100870. https://doi.org/10.1016/j.mam.2020.100870
6. Muntasell, A., Ochoa, M. C., Cordeiro, L., Berraondo, P., Lopez-Diaz de Cerio, A., Cabo, M., Lopez-Botet, M., & Melero, I. (2017). Targeting NK-cell checkpoints for cancer immunotherapy. Current Opinion in Immunology, 45, 73-81. https://doi.org/10.1016/j.coi.2017.01.003
Long Name
Fc gamma Receptor III A
Alternate Names
CD16a, FCGR3A, FcgRIIIA
Gene Symbol
FCGR3A
Additional Fc gamma RIIIA/CD16a Products
Product Documents for Fc gamma RIIIA/CD16a Antibody (DJ130c) [DyLight 488]
Product Specific Notices for Fc gamma RIIIA/CD16a Antibody (DJ130c) [DyLight 488]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...